Support for two Clinical Staff Investigators, Drs Mohammed Milhem and Daniel Vaena, is requested. Milhem and Vaena are both outstanding young clinical investigators. They qualify for Staff Investigator support because of the important roles they play in the clinical activities of the center. They also play a definable and special role in helping the center achieve scientific objectives. Mohammed Milhem, M.D., is being proposed as a Clinical Staff Investigator in recognition of his efforts coordinating the clinical research taking place in the Multidisciplinary Oncology Groups (MOGs) of the HCCC. Dr Milhem's formal title within the HCCC is """"""""Assistant Director for Multidisciplinary Clinical Research"""""""". He also is developing a robust clinical research program in melanoma and sarcoma, and leading the collaborative phase II clinical trials activities of the HCCC. Dr Daniel Vaena is being proposed for Clinical Staff Investigator support based on his contributions to clinical research at the HCCC including oversight of clinical research support services and his extensive participation in cooperative group activities. Dr Vaena's formal title within the Cancer Center is """"""""Assistant Director for Clinical Research Services"""""""".

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381297
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$78,560
Indirect Cost
$32,875
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773
Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358
Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408
Spencer Noakes, T Leigh; Przybycien, Thomas S; Forwell, Amanda et al. (2018) Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. Clin Cancer Res 24:6040-6052

Showing the most recent 10 out of 1080 publications